Maze Therapeutics Inc
MAZE8.210
+0.510+6.62%
Close 04/25, 16:00（ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Maze Therapeutics Inc Company
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Company Info
Company codeMAZE
Company nameMaze Therapeutics Inc
IPO dateJan 31, 2025
Founded at2017
CEODr. Jason V. Coloma, Ph.D.
Number of employees125
Security typeOrdinary Share
Fiscal year-endJan 31
Address171 Oyster Point Boulevard, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94080
Phone16508505070
Websitehttps://www.mazetx.com/
Company codeMAZE
IPO dateJan 31, 2025
Founded at2017
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
20.74K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Ms. Jillian Connell
Ms. Jillian Connell
Investor Relations
Investor Relations
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
20.74K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Apr 27
Update time: Sun, Apr 27
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Third Rock Ventures, LLC
16.04%
ARCH Venture Partners
9.41%
Frazier Life Sciences Management, L.P.
7.29%
Deep Track Capital LP
6.90%
Matrix Capital Management Company, LP
5.68%
Other
54.68%
Shareholder Statistics
Shareholder
Proportion
Third Rock Ventures, LLC
16.04%
ARCH Venture Partners
9.41%
Frazier Life Sciences Management, L.P.
7.29%
Deep Track Capital LP
6.90%
Matrix Capital Management Company, LP
5.68%
Other
54.68%
Type
Shareholder
Proportion
Venture Capital
27.81%
Private Equity
12.90%
Investment Advisor/Hedge Fund
8.50%
Hedge Fund
6.90%
Individual Investor
5.91%
Corporation
5.51%
Investment Advisor
2.60%
Family Office
1.10%
Other
28.77%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
16
30.56M
69.78%
+23.42M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Third Rock Ventures, LLC
12.79M
29.2%
+5.76M
+82.04%
Feb 03, 2025
ARCH Venture Partners
4.12M
9.41%
+4.12M
--
Jan 31, 2025
Deep Track Capital LP
3.02M
6.9%
+3.02M
--
Jan 31, 2025
Matrix Capital Management Company, LP
2.49M
5.68%
+2.49M
--
Jan 31, 2025
Foresite Capital Management, LLC
2.46M
5.61%
+2.46M
--
Jan 31, 2025
Alphabet Holdings L.L.C.
2.41M
5.51%
+2.41M
--
Jan 31, 2025
Brush (James)
1.63M
3.73%
+1.63M
--
Jan 31, 2025
The Vanguard Group, Inc.
49.15K
0.11%
+348.00
+0.71%
Feb 28, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data